AGÕæÈ˹ٷ½

STOCK TITAN

[6-K] Adagene Inc. American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-
16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of July 2025

 

Commission File Number: 001-39997

 

 

 

Adagene Inc.

 

 

 

4F, Building C14, No. 218

Xinghu Street, Suzhou Industrial Park

Suzhou, Jiangsu Province, 215123

People’s Republic of China

+86-512-8777-3632

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x   Form 40-F ¨

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Adagene Inc.
   
  By: /s/ Peter Luo
  Name: Peter Luo
  Title: Chief Executive Officer
   
Date: July 15, 2025  

 

 

 

 

EXHIBIT INDEX

 

Exhibit   Description
     
99.1   Press release titled “Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA.”

 

 

 

Adagene Inc.

NASDAQ:ADAG

ADAG Rankings

ADAG Latest News

ADAG Latest SEC Filings

ADAG Stock Data

112.64M
41.09M
4.7%
31.63%
0.12%
Biotechnology
Healthcare
China
Suzhou